| Product Code: ETC6185899 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Australia`s narcotic drugs market is highly regulated, with strict control under the Therapeutic Goods Administration (TGA) and compliance with international drug control treaties. The market includes pharmaceutical opioids for pain management, palliative care, and anesthesia. However, recent policy shifts aimed at reducing opioid dependency and misuse have led to tighter prescribing practices, changes in scheduling, and promotion of non-opioid alternatives. These regulatory dynamics are reshaping demand and innovation in this sector.
The Australia narcotic drugs market is under transition as regulatory scrutiny intensifies and opioid prescription guidelines are tightened to curb misuse. Despite these regulatory challenges, the demand for narcotic analgesics remains stable for chronic pain and cancer-related treatments. There is also increased emphasis on opioid alternatives and multimodal pain management strategies.
Australia`s narcotic drugs market faces complex regulatory and societal challenges. Strict regulatory controls around the manufacturing, prescription, and distribution of narcotic drugs limit market growth, even for legitimate therapeutic use. The heightened concern over opioid abuse and addiction has led to tighter government scrutiny and controlled substance management programs. This has resulted in healthcare providers being cautious about prescribing, thus restricting demand. Additionally, public perception and growing awareness of opioid misuse continue to influence policymaking, often limiting access to patients who may genuinely benefit from narcotic analgesics.
The narcotic drugs market in Australia is shaped by a strict regulatory environment, yet it offers opportunities in the development of abuse-deterrent formulations, controlled drug distribution technologies, and personalized pain management therapies. Companies engaged in medical cannabis production or research can also benefit from evolving policy support and rising demand for opioid alternatives.
The Australian government exercises strict control over the narcotic drugs market under the Narcotic Drugs Act 1967 and the Therapeutic Goods Act 1989. The Office of Drug Control (ODC) regulates licensing for the manufacture and supply of narcotics for medical and scientific purposes. Policies ensure narcotic drug distribution complies with international treaties such as the Single Convention on Narcotic Drugs. Governmental measures aim to balance patient access with minimizing the risk of misuse and diversion.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Narcotic Drugs Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Narcotic Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Narcotic Drugs Market - Industry Life Cycle |
3.4 Australia Narcotic Drugs Market - Porter's Five Forces |
3.5 Australia Narcotic Drugs Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.6 Australia Narcotic Drugs Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 Australia Narcotic Drugs Market Revenues & Volume Share, By Drug, 2021 & 2031F |
3.8 Australia Narcotic Drugs Market Revenues & Volume Share, By Administration, 2021 & 2031F |
3.9 Australia Narcotic Drugs Market Revenues & Volume Share, By End users, 2021 & 2031F |
4 Australia Narcotic Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chronic pain conditions in Australia |
4.2.2 Aging population leading to higher demand for pain management medications |
4.2.3 Growing acceptance and adoption of opioid-based treatments in healthcare |
4.3 Market Restraints |
4.3.1 Stringent regulations and monitoring of narcotic drugs due to abuse potential |
4.3.2 Rising concerns and awareness about opioid addiction and misuse |
5 Australia Narcotic Drugs Market Trends |
6 Australia Narcotic Drugs Market, By Types |
6.1 Australia Narcotic Drugs Market, By Source |
6.1.1 Overview and Analysis |
6.1.2 Australia Narcotic Drugs Market Revenues & Volume, By Source, 2021- 2031F |
6.1.3 Australia Narcotic Drugs Market Revenues & Volume, By Natural, 2021- 2031F |
6.1.4 Australia Narcotic Drugs Market Revenues & Volume, By Semi-synthetic, 2021- 2031F |
6.1.5 Australia Narcotic Drugs Market Revenues & Volume, By Synthetic, 2021- 2031F |
6.2 Australia Narcotic Drugs Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Australia Narcotic Drugs Market Revenues & Volume, By Pain Management, 2021- 2031F |
6.2.3 Australia Narcotic Drugs Market Revenues & Volume, By Cough, 2021- 2031F |
6.2.4 Australia Narcotic Drugs Market Revenues & Volume, By Diarrhea, 2021- 2031F |
6.2.5 Australia Narcotic Drugs Market Revenues & Volume, By Dysentery, 2021- 2031F |
6.2.6 Australia Narcotic Drugs Market Revenues & Volume, By Asthma, 2021- 2031F |
6.2.7 Australia Narcotic Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Australia Narcotic Drugs Market, By Drug |
6.3.1 Overview and Analysis |
6.3.2 Australia Narcotic Drugs Market Revenues & Volume, By Opium, 2021- 2031F |
6.3.3 Australia Narcotic Drugs Market Revenues & Volume, By Heroin, 2021- 2031F |
6.3.4 Australia Narcotic Drugs Market Revenues & Volume, By Codeine, 2021- 2031F |
6.3.5 Australia Narcotic Drugs Market Revenues & Volume, By Oxycodone, 2021- 2031F |
6.3.6 Australia Narcotic Drugs Market Revenues & Volume, By Hydrocodone, 2021- 2031F |
6.3.7 Australia Narcotic Drugs Market Revenues & Volume, By Tramadol, 2021- 2031F |
6.3.8 Australia Narcotic Drugs Market Revenues & Volume, By Fentanyl, 2021- 2031F |
6.3.9 Australia Narcotic Drugs Market Revenues & Volume, By Fentanyl, 2021- 2031F |
6.3.10 Australia Narcotic Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Australia Narcotic Drugs Market, By Administration |
6.4.1 Overview and Analysis |
6.4.2 Australia Narcotic Drugs Market Revenues & Volume, By Oral, 2021- 2031F |
6.4.3 Australia Narcotic Drugs Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.4.4 Australia Narcotic Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Australia Narcotic Drugs Market, By End users |
6.5.1 Overview and Analysis |
6.5.2 Australia Narcotic Drugs Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.3 Australia Narcotic Drugs Market Revenues & Volume, By Homecare, 2021- 2031F |
6.5.4 Australia Narcotic Drugs Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.5.5 Australia Narcotic Drugs Market Revenues & Volume, By Others, 2021- 2031F |
7 Australia Narcotic Drugs Market Import-Export Trade Statistics |
7.1 Australia Narcotic Drugs Market Export to Major Countries |
7.2 Australia Narcotic Drugs Market Imports from Major Countries |
8 Australia Narcotic Drugs Market Key Performance Indicators |
8.1 Number of prescriptions for narcotic drugs |
8.2 Percentage of healthcare professionals trained in responsible opioid prescribing practices |
8.3 Patient satisfaction with pain management treatments |
9 Australia Narcotic Drugs Market - Opportunity Assessment |
9.1 Australia Narcotic Drugs Market Opportunity Assessment, By Source, 2021 & 2031F |
9.2 Australia Narcotic Drugs Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 Australia Narcotic Drugs Market Opportunity Assessment, By Drug, 2021 & 2031F |
9.4 Australia Narcotic Drugs Market Opportunity Assessment, By Administration, 2021 & 2031F |
9.5 Australia Narcotic Drugs Market Opportunity Assessment, By End users, 2021 & 2031F |
10 Australia Narcotic Drugs Market - Competitive Landscape |
10.1 Australia Narcotic Drugs Market Revenue Share, By Companies, 2024 |
10.2 Australia Narcotic Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here